Markets· August 17, 2026 at 03:03 p.m.
Greenhaven Road Capital Investments: AnaptysBio (ANAB) and GSK Acquisition Speculation
Key takeaways
- Greenhaven Road Capital added AnaptysBio (ANAB) to its portfolio
- AnaptysBio's cancer drug Jemperli is expected to generate over $1 billion in revenue for GSK in 2026
- Jemperli royalties account for nearly all of ANAB's business
Investment management firm Greenhaven Road Capital has added biotechnology company AnaptysBio, Inc. (NASDAQ: ANAB) to its portfolio. The company focuses on immunology therapeutics for autoimmune and inflammatory diseases. As of August 14, 2026, ANAB closed at $58.47 per share with a market capitalization of $1.73 billion. The stock posted a one-month return of 16.27% and gained 338.15% over the past 52 weeks. Greenhaven Road Capital views AnaptysBio as an investment that may not require significant patience due to its potential for near-term catalysts.
